Skip to main content

Table 3 Summary of the biomarkers that are significantly different between neurodegenerative disorders

From: Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic

 

Aβ1–42

T-tau

T-tau/Aβ1–42

P-tau

NFL

AβX-42

AβX-42/X-40

APPα

APPβ

AD vs DLB

 

+

++

+

++

+

++

  

+

+

+

AD vs bvFTD

+

++

+

++

+++

+

++

+

+

++

+

++

+

++

+

++

AD vs PNFA

+

 

+

 

+

++

    

AD vs SD

+

++

+

++

+

++

+

++

+

++

+

++

+

++

  

DLB vs bvFTD

+

++

 

+

  

+

   

DLB vs PNFA

 

+

 

+

+

  

+

+

DLB vs SD

+

++

 

+

 

+

+

+

  

bvFTD vs PNFA

 

+

++

+

++

+

  

+

+

++

+

++

bvFTD vs SD

         

PNFA vs SD

+

+

+

++

+

  

+

  
  1. Biomarkers with “+” distinguish between groups with p < 0.05 from the unadjusted analysis, and “++” distinguish between groups with Bonferroni corrected p < 0.003
  2. amyloid beta, AD Alzheimer’s disease, APP amyloid precursor protein, bvFTD behavioural variant frontotemporal dementia, DLB dementia with Lewy bodies, PNFA progressive non-fluent aphasia, SD Semantic dementia, NFL neurofilament light chain, P-tau phosphorylated tau, T-tau total tau